Expert available on recent FDA analysis of TNF blockers

Aug 9 2009

Lloyd J. Old, M.D., is Director of the Ludwig Institute for Cancer Research (LICR) New York Branch. He is also Director of the Cancer Research Institute (CRI) Scientific Advisory Council, Director of the CRI/LICR Cancer Vaccine Collaborative, and Director of the CRI Cancer Vaccine Consortium. He has been a Member of the National Academy of Sciences since 1978.

Dr. Old’s previous appointments include LICR Scientific Director (1988 to 2005), Chairman of the LICR Board of Directors (2005-2009), Member of the Emeritus LICR Scientific Committee (1971-86), LICR Chief Executive Officer (1995-2004), and Associate Director of Research at Memorial Sloan-Kettering Cancer Center (1973-83).

He has been associated with the Memorial Sloan-Kettering Cancer Center since 1958, first as a research fellow. He was appointed Associate Director of Research in 1973 of Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and Allied Diseases and was named the William E. Snee Chair of Cancer Immunology in 1983.

In 1975, Lloyd J. Old, M.D., identified tumor necrosis factor-alpha, the target of therapies cited in the FDA report that treat diseases like rheumatoid arthritis, Crohn's disease, and other immune disorders. He is one of the pioneers in tumor immunology, having made some of the most important contributions to that field from both the lab bench and the board room table. As the discoverer of TNF-alpha and as one of the leading tumor immunologists, he is qualified to provide insight into the relationship between cancer, the immune system, TNF-alpha, and the benefits and risks of anti-TNF-alpha therapeutics.

He is one of the most highly cited researchers in the field, and is an international award-winning scientific luminary who has helped to forge alliances among academic and industry interests in order to accelerate the scientifically prudent advancement of cancer vaccines.

http://www.cancerresearch.org/board/Lloyd-Old.html